Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin degludec versus insulin glargine crossover trial in adults with type 1 diabetes
2012-001930-32Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of insulin degludec, insulin glargine and insulin aspart in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic episodes during the maintenance period. Started Jul 2014; status: completed.
02
Drugs
insulin degludecinsulin glargineinsulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2012-001930-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001930-32.